Skip to content

Clinical trials

Phase 1/2 Small Cell Lung Carcinoma trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Small Cell Lung Carcinoma Phase: Phase 1/2 Country / region: United States Clear all

108 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20031
20041
20061
20074
20082
20091
20103
20124
20135
20146
20155
20165
201710
20185
20197
202010
20217
20223
20235
20257
202612

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed40
Recruiting26
Terminated25
Active, not recruiting10
Unknown status4
Withdrawn2
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)11
Incyte Biosciences International Sàrl3
Washington University School of Medicine3
AbbVie2
Amgen2
Astellas Pharma Global Development, Inc.2
BioNTech SE2
Boehringer Ingelheim2
Bristol-Myers Squibb2
G1 Therapeutics, Inc.2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Small Cell Lung Carcinoma108
Carcinoma, Non-Small-Cell Lung33
Lung Neoplasms17
Ovarian Neoplasms16
Breast Neoplasms14
Squamous Cell Carcinoma of Head and Neck14
Stomach Neoplasms14
Triple Negative Breast Neoplasms14
Uterine Cervical Neoplasms13
Colorectal Neoplasms12

Trials

Showing 1 to 25 of 108. Each trial links to its page on Pharma Observatory.

8 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.